2022 Shanghai International Biomedical Industry ended Sunday with a total investment of 32.5 billion yuan. In recent years, the scale of Shanghai's bio pharmaceutical industry has been expanding, from 383.3 billion yuan in 2019 to 761.7 billion yuan in 2021. In the first three quarters of this year, the scale of Shanghai's bio pharmaceutical industry reached 616.6 billion yuan, up 4.6% year on year. Why does the biopharmaceutical industry in Shanghai develop rapidly and become an important support for high-quality development? The reporter conducted an interview. A new trend of integrated development has been formed: "The rapid development of Shanghai's bio pharmaceutical industry is due to the continuous gathering of bio pharmaceutical enterprises." Wu Jincheng, director of the Shanghai Economic and Information Technology Commission, said. In the 1990s, with the development and opening up of Pudong, Roche Pharmaceuticals landed in Zhangjiang and became the first well-known multinational pharmaceutical company to enter Shanghai. Since then, world famous pharmaceutical enterprises have successively entered Shanghai. Today, the biopharmaceutical industry in Shanghai has formed a new trend of integrated development of multiple pharmaceutical enterprises. Wu Qiang, deputy head of Pudong New Area, said that at present, there are more than 2600 biomedical enterprises in Pudong, including 1700 in Zhangjiang Pharmaceutical Valley alone. The gathering of biomedical enterprises brings about the gathering of talents. The White Paper on Talent Development of Shanghai Biomedical Industry released on this industry week shows that there are 278000 practitioners in Shanghai's biomedical industry. The talent gathering brings about the biomedical technology gathering and capital gathering. In 2021, there will be 116 new drugs of Class I approved for the first time in Zhangjiang, a year-on-year increase of 45%; Zhangjiang biopharmaceutical enterprises obtained a total of 52.541 billion yuan of venture capital, with a year-on-year growth rate of 62.99%. Another important factor in accelerating the convergence of biomedical enterprises in Shanghai is the continuously optimized business environment in Shanghai. On November 11, the first innovation base of scientists from the world famous medical laser equipment enterprises in China was opened in the Waigaoqiao Free Trade Zone. It only took more than 60 days from signing the contract to the completion of the production base and R&D center. Zhai Qiying, senior president of Asia, a medical scientist, said: "A high-tech modern chemical plant has been built in such a short time, and we have personally experienced the excellent business environment in Shanghai." "This kind of environment is not only reflected in efficiency, but also in the industrial environment and institutional environment." Chen Li, founder of Hualing Pharmaceutical, said. In recent years, Shanghai has experimented with a series of new systems such as the drug marketing license holder system. R&D enterprises can adopt the entrustment mode in drug production and sales, creating conditions for rapid R&D with concentrated advantages. The excellent office environment, high-level laboratories, and on-demand experimental services... The dart innovation center of the biomedical professional incubator gave reporters a glimpse. "The innovation center serves the research and development of new drugs. We provide laboratories and instruments, and even laboratory personnel and managers." Zhu Pengcheng, the founder of Dart Innovation Center, said that in the past five years, the center has served more than 120 enterprises or projects, and the enterprises served have accumulated more than 10 billion yuan of investment. The research and development achievements of gene therapy for heart disease, artificial liver and other projects have shown initial results. Accelerate the layout of key new tracks At the opening ceremony of this industry week, Shanghai's biomedical industry chain